Comparative Pharmacology
Head-to-head clinical analysis: ANCEF versus KEFLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF versus KEFLET.
ANCEF vs KEFLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Keflet (warfarin) inhibits vitamin K epoxide reductase, preventing the recycling of vitamin K and thereby reducing the synthesis of clotting factors II, VII, IX, and X in the liver.
1-2 g IV/IM every 8 hours; maximum 6 g/day.
500 mg orally every 12 hours for 10-14 days; for uncomplicated UTI: 250 mg orally every 12 hours for 7 days.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolongs significantly in renal impairment (up to 30 hours in anuria).
0.5-1 hour; prolonged in renal impairment (up to 20-30 hours in ESRD).
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); small amounts biliary (<1%) and fecal.
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic